ProKidney Corp. (PROK) stock

PROKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30

$1.04−0.10 (-9.13%)

Close on Nov 13, 2026Market cap $315.93MP/E –Yield –

ProKidney cash

Cash and short-term investments held at the end of each period.

ProKidney's cash was $81.36M at Sep 30, 2026. For fiscal 2025 it was $108.54M, up 9.5% from the year before. The highest annual figure on record is $490.25M in fiscal 2022.

Annual cash

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$108.54M	+9.5%
FY2024	Dec 31, 2024	$99.12M	+63.4%
FY2023	Dec 31, 2023	$60.65M	-87.6%
FY2022	Dec 31, 2022	$490.25M	+2284.7%
FY2021	Dec 31, 2021	$20.56M	+349.1%
FY2020	Dec 31, 2020	$4.58M	-69.9%
FY2019	Dec 31, 2019	$15.23M	–

Quarterly cash

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$81.36M	-14.7%
Q2 FY2026	Jun 30, 2026	$74.87M	-11.9%
Q1 FY2026	Mar 31, 2026	$101.90M	+4.2%
Q4 FY2025	Dec 31, 2025	$108.54M	+9.5%
Q3 FY2025	Sep 30, 2025	$95.32M	-11.8%
Q2 FY2025	Jun 30, 2025	$84.94M	-60.4%
Q1 FY2025	Mar 31, 2025	$97.81M	+15.9%
Q4 FY2024	Dec 31, 2024	$99.12M	+63.4%
Q3 FY2024	Sep 30, 2024	$108.09M	-43.5%
Q2 FY2024	Jun 30, 2024	$214.51M	-11.9%
Q1 FY2024	Mar 31, 2024	$84.39M	-68.9%
Q4 FY2023	Dec 31, 2023	$60.65M	-87.6%
Q3 FY2023	Sep 30, 2023	$191.39M	-62.2%
Q2 FY2023	Jun 30, 2023	$243.55M	+1013.0%
Q1 FY2023	Mar 31, 2023	$271.64M	+811.5%
Q4 FY2022	Dec 31, 2022	$490.25M	+2284.7%
Q3 FY2022	Sep 30, 2022	$506.33M	+12264.5%
Q2 FY2022	Jun 30, 2022	$21.88M	+9688.9%
Q1 FY2022	Mar 31, 2022	$29.80M	–
Q4 FY2021	Dec 31, 2021	$20.56M	+349.1%
Q3 FY2021	Sep 30, 2021	$4.10M	-73.1%
Q2 FY2021	Jun 30, 2021	$223.54K	–
Q1 FY2021	Mar 31, 2021	$0	–
Q4 FY2020	Dec 31, 2020	$4.58M	–
Q4 FY2019	Dec 31, 2019	$15.23M	–